Difference between revisions of "Disopyramide"
From Self-sufficiency
m (Stub sorting and placement of stub template(s)) |
m (1 revision) |
(No difference)
| |
Latest revision as of 15:48, 19 September 2010
| File:Disopyramide.svg | |
| File:Disopramide.png | |
| Systematic (IUPAC) name | |
|---|---|
|
4-(diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide | |
| Clinical data | |
| Pregnancy category | |
| Routes of administration | Oral, intravenous |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | High |
| Protein binding |
50% to 65% (concentration-dependent) |
| Metabolism | Hepatic (CYP3A4-mediated) |
| Biological half-life | 6.7 hours (range 4 to 10 hours) |
| Excretion | Renal (80%) |
| Identifiers | |
| CAS Number | 3737-09-5 |
| ATC code | C01BA03 (WHO) |
| PubChem | CID 3114 |
| DrugBank | APRD00507 |
| ChemSpider | 3002 |
| Chemical data | |
| Formula | C21H29N3O |
| Molar mass | 339.475 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
| (verify) | |
Disopyramide (INN, trade names Norpace and Rythmodan) is an antiarrhythmic medication. It is a Class Ia antiarrhythmic (sodium channel blocker) used in the treatment of ventricular tachycardias. It has no effect on alpha or beta adrenergic receptors. It resembles Quinidine but it has a marked anti-muscarinic effect on the heart, for this reason, it is not considered as a drug of 1st choice. It is also used in ventricular arrhythmia and supraventricular arrhythmia that might follow myocardial infarctions.
Cardiac adverse effects
Extracardiac effects
- Dry mouth
- Constipation
- Urinary retention
- Blurred vision
- Glaucoma
- Rash
- Agranulocytosis
Chemistry
External links
| 30px | This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it. |
es:Disopiramida fr:Disopyramide hr:Diizopiramid it:Disopiramide pl:Dizopiramid
